TABLE 2.
Prevalence of baseline polymorphisms in GT1a-infected patients
| Target and variant | %a |
|---|---|
| NS3 (nb = 230) | |
| V36A | 0.9 |
| V36L | 1.3 |
| V36M | 0.9 |
| Q80K | 41 |
| Q80L | 2.2 |
| D168A | 0.4 |
| NS5 (n = 235) | |
| M28T | 0.4 |
| M28V | 6.0 |
| L31M | 0.4 |
| L31V | 0.4 |
| Q30H | 2.1 |
| Q30R | 1.3 |
| H58C | 0.4 |
| H58P | 1.7 |
| H58Q | 0.9 |
| H58R | 1.3 |
| H58Y | 0.4 |
| Y93C | 0.4 |
| Y93H | 1.3 |
| Y93N | 0.4 |
| NS5B (n = 258) | |
| C316Y | 0.8 |
| M414T | 0.4 |
| A553G | 0.4 |
| S556G | 3.1 |
| S556N | 0.4 |
| S556R | 0.4 |
a
Percentage of patients with the baseline polymorphism relative to the GT1a strain H77 reference sequence.
b
n, number of samples sequenced for that target.